Graves’ Disease Treatment
Jan 24, 2025
Graves’ Disease Drug Pipeline: 6 Late-Stage Therapies to Watch
The pipeline for Graves’ disease drug treatments is rapidly expanding, with prominent companies such as Immunovant, Viridian Therapeutics, Argenx, Tourmaline Bio, Hoffmann-La Roche, and Sling Therapeutics spearheading the development of targeted therapies for thyroid disorders. Promising candidates in the late stag...
Read More...
Jan 17, 2025
Graves’ Disease Treatment Revolution: What’s Next in Line?
Affecting around 1 in 200 people, Graves’ disease is the most common cause of an overactive thyroid. More than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. As per DelveInsight’s estimates, Graves’ disease...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
